Lindgardt Zhenya sold $43K of SERA

Lindgardt Zhenya (Chief Executive Officer) sold 20,755 shares of SERA PROGNOSTICS, INC. (SERA) at $2.08 on 2026-06-09.

Original reporting
SEC EDGAR · Lindgardt Zhenya
Published Jun 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
medium confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

An officer/director open-market sale can modestly affect retail sentiment, but without any accompanying corporate disclosure it typically has limited trading impact.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to be a standalone catalyst.

03

What to watch

The article doesn’t state whether other insiders/large holders are buying, nor does it provide context for the sale (e.g., tax event, planned diversification).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10; transaction dated 2026-06-09

Background

The article is an SEC Form 4 insider transaction filing for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralMedium confidence
Context

SERA CEO Lindgardt Zhenya filed an open-market sale of 20,755 shares at $2.0800 on 2026-06-09 (Form 4).

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 insider sales are common and the article provides no accompanying corporate event (no guidance, deal, or enforcement action). The sale is also not stated as part of a 10b5-1 plan, but the disclosure alone still lacks a direct business impact.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • SERA PROGNOSTICS, INC.

    Company whose shares were sold by its CEO via an open-market transaction disclosed on Form 4.

  • Lindgardt Zhenya

    CEO and officer/director who sold 20,755 shares at $2.0800 on 2026-06-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t